TY - JOUR
T1 - Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases
AU - Cassoni, Paola
AU - Daniele, Lorenzo
AU - Maldi, Elena
AU - Righi, Luisella
AU - Tavaglione, Veronica
AU - Novello, Silvia
AU - Volante, Marco
AU - Scagliotti, Giorgio Vittorio
AU - Papotti, Mauro
PY - 2009/7
Y1 - 2009/7
N2 - Aims: To study caveolin-1 (Cav-1) expression in metastatic lung carcinomas. Methods and results: Cav-1 expression was investigated in a series of 121 lung carcinomas and it was shown that 18 / 121 tumours (14.9%) were Cav-1+. None of the pure bronchioloalveolar carcinomas proved to be positive, vs. 42.8% of the large cell carcinomas (neuroendocrine subtype excluded). Adenocarcinomas (8.5%), large cell neuroendocrine carcinomas (20%) and squamous cell carcinomas (29.6%) displayed an intermediate percentage of positive cases, suggesting a gradient of Cav-1 expression according to tumour histotype-related aggressiveness. Moreover, the percentage of Cav-1+ tumours with distant metastases was almost double that of non-metastatic tumours (17.8% vs. 8.1%), irrespective of the histotype. In 34 tumours metastatic to the brain, primary and secondary lesions were compared and 53% of brain metastases were Cav-1+ vs. 20.6% of primaries, indicating a de novo acquisition of Cav-1 expression. This pattern was exclusive to the brain, as it was not acquired in adrenal metastases. In our series, the presence of epidermal growth factor receptor amplification, determined by fluorescence in situ hybridization, was not related to Cav-1 reactivity. Conclusions: Cav-1 immunoreactivity in lung carcinoma is histotype-dependent and acquired de novo in brain metastases, suggesting a site-specific phenotypic shift in secondary lesions.
AB - Aims: To study caveolin-1 (Cav-1) expression in metastatic lung carcinomas. Methods and results: Cav-1 expression was investigated in a series of 121 lung carcinomas and it was shown that 18 / 121 tumours (14.9%) were Cav-1+. None of the pure bronchioloalveolar carcinomas proved to be positive, vs. 42.8% of the large cell carcinomas (neuroendocrine subtype excluded). Adenocarcinomas (8.5%), large cell neuroendocrine carcinomas (20%) and squamous cell carcinomas (29.6%) displayed an intermediate percentage of positive cases, suggesting a gradient of Cav-1 expression according to tumour histotype-related aggressiveness. Moreover, the percentage of Cav-1+ tumours with distant metastases was almost double that of non-metastatic tumours (17.8% vs. 8.1%), irrespective of the histotype. In 34 tumours metastatic to the brain, primary and secondary lesions were compared and 53% of brain metastases were Cav-1+ vs. 20.6% of primaries, indicating a de novo acquisition of Cav-1 expression. This pattern was exclusive to the brain, as it was not acquired in adrenal metastases. In our series, the presence of epidermal growth factor receptor amplification, determined by fluorescence in situ hybridization, was not related to Cav-1 reactivity. Conclusions: Cav-1 immunoreactivity in lung carcinoma is histotype-dependent and acquired de novo in brain metastases, suggesting a site-specific phenotypic shift in secondary lesions.
KW - Adrenal metastasis
KW - Brain metastasis
KW - Caveolin-1
KW - Lung carcinoma
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=68049140927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68049140927&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2559.2009.03326.x
DO - 10.1111/j.1365-2559.2009.03326.x
M3 - Article
C2 - 19614763
AN - SCOPUS:68049140927
VL - 55
SP - 20
EP - 27
JO - Histopathology
JF - Histopathology
SN - 0309-0167
IS - 1
ER -